中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2014年
21期
1358-1362
,共5页
任艳飞%袁秀丽%岳丽杰%邹泽巧%谢偲%丁慧%宋萍%刘畅
任豔飛%袁秀麗%嶽麗傑%鄒澤巧%謝偲%丁慧%宋萍%劉暢
임염비%원수려%악려걸%추택교%사시%정혜%송평%류창
谷胱甘肽转移酶%基因多态性%急性淋巴细胞白血病%甲氨蝶呤%不良反应
穀胱甘肽轉移酶%基因多態性%急性淋巴細胞白血病%甲氨蝶呤%不良反應
곡광감태전이매%기인다태성%급성림파세포백혈병%갑안접령%불량반응
glutathione S-transferase pi%gene polymorphism%acute lymphoblastic leukemia%methotrexate%toxicity
目的:研究谷胱甘肽转移酶P1(glutathione S-transferase pi,GSTP1)基因多态性与儿童急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)使用大剂量甲氨蝶呤(high-dose methotrexate,HD-MTX)化疗后不良反应的关系。方法:应用巢式PCR(Nest PCR)、变性梯度凝胶电泳(denaturing gel gradient electrophoresis,DGGE)和DNA直接测序技术检测51例儿童ALL GSTP1基因型和等位基因分布频率,按美国国立癌症研究所的常规毒性判定标准(NCICTCAE)对HD-MTX不良反应进行统计分析。结果:筛查出3个GSTP1 SNPs位点即rs1695(A313G)、rs1138272(G439T)和rs4891(T555C)。rs1695/rs4891多态性位点包括32例(62.7%)野生型、16例(31.4%)杂合型和3例(5.9%)纯合型,rs1138272多态性位点仅包括1例(2.0%)杂合型和1例(2.0%)纯合型。3个SNPs位点等位基因频率分别为21.6%、2.9%和21.6%。GSTP1 rs1695/rs4891多态性位点中AG+GG/TC+CC基因型与外周血血红蛋白减少有关(OR=0.25,95%CI=0.06~1.00,P=0.049),GSTP1 rs1695/rs4891多态性位点中AG+GG/TC+CC基因型与高危组患儿胃肠毒性发生有关(OR=0.125,95%CI=0.02~0.78,P=0.026)。结论:GSTP1 rs1695/rs4891多态性与ALL儿童HD-MTX化疗后外周血血红蛋白降低以及中高危组ALL儿童发生胃肠毒性有关。
目的:研究穀胱甘肽轉移酶P1(glutathione S-transferase pi,GSTP1)基因多態性與兒童急性淋巴細胞白血病(acute lymphoblastic leukemia,ALL)使用大劑量甲氨蝶呤(high-dose methotrexate,HD-MTX)化療後不良反應的關繫。方法:應用巢式PCR(Nest PCR)、變性梯度凝膠電泳(denaturing gel gradient electrophoresis,DGGE)和DNA直接測序技術檢測51例兒童ALL GSTP1基因型和等位基因分佈頻率,按美國國立癌癥研究所的常規毒性判定標準(NCICTCAE)對HD-MTX不良反應進行統計分析。結果:篩查齣3箇GSTP1 SNPs位點即rs1695(A313G)、rs1138272(G439T)和rs4891(T555C)。rs1695/rs4891多態性位點包括32例(62.7%)野生型、16例(31.4%)雜閤型和3例(5.9%)純閤型,rs1138272多態性位點僅包括1例(2.0%)雜閤型和1例(2.0%)純閤型。3箇SNPs位點等位基因頻率分彆為21.6%、2.9%和21.6%。GSTP1 rs1695/rs4891多態性位點中AG+GG/TC+CC基因型與外週血血紅蛋白減少有關(OR=0.25,95%CI=0.06~1.00,P=0.049),GSTP1 rs1695/rs4891多態性位點中AG+GG/TC+CC基因型與高危組患兒胃腸毒性髮生有關(OR=0.125,95%CI=0.02~0.78,P=0.026)。結論:GSTP1 rs1695/rs4891多態性與ALL兒童HD-MTX化療後外週血血紅蛋白降低以及中高危組ALL兒童髮生胃腸毒性有關。
목적:연구곡광감태전이매P1(glutathione S-transferase pi,GSTP1)기인다태성여인동급성림파세포백혈병(acute lymphoblastic leukemia,ALL)사용대제량갑안접령(high-dose methotrexate,HD-MTX)화료후불량반응적관계。방법:응용소식PCR(Nest PCR)、변성제도응효전영(denaturing gel gradient electrophoresis,DGGE)화DNA직접측서기술검측51례인동ALL GSTP1기인형화등위기인분포빈솔,안미국국립암증연구소적상규독성판정표준(NCICTCAE)대HD-MTX불량반응진행통계분석。결과:사사출3개GSTP1 SNPs위점즉rs1695(A313G)、rs1138272(G439T)화rs4891(T555C)。rs1695/rs4891다태성위점포괄32례(62.7%)야생형、16례(31.4%)잡합형화3례(5.9%)순합형,rs1138272다태성위점부포괄1례(2.0%)잡합형화1례(2.0%)순합형。3개SNPs위점등위기인빈솔분별위21.6%、2.9%화21.6%。GSTP1 rs1695/rs4891다태성위점중AG+GG/TC+CC기인형여외주혈혈홍단백감소유관(OR=0.25,95%CI=0.06~1.00,P=0.049),GSTP1 rs1695/rs4891다태성위점중AG+GG/TC+CC기인형여고위조환인위장독성발생유관(OR=0.125,95%CI=0.02~0.78,P=0.026)。결론:GSTP1 rs1695/rs4891다태성여ALL인동HD-MTX화료후외주혈혈홍단백강저이급중고위조ALL인동발생위장독성유관。
Objective:To investigate the association between glutathione S-transferase pi (GSTP1) gene polymorphism and toxici-ties related to high-dose methotrexate (HD-MTX) in children with acute lymphoblastic leukemia (ALL). Methods:GSTP1 genotypes and allelic frequencies in 51 children with ALL were determined by Nest PCR, denaturing gel gradient electrophoresis (DGGE), and DNA sequencing. HD-MTX adverse reactions were analyzed using the National Cancer Institute Common Toxicity Criteria (NCICTC). Results:We identified three SNPs of GSTP1, including rs1695 (A313G), rs1138272 (G439T), and rs4891 (T555C). The wild types, het-erozygous types, and homozygous types of GSTP1 rs1695/rs4891 polymorphisms were detected in 32 cases (62.7%), 16 cases (31.4%), and 3 cases (5.9%), respectively. GSTP1 rs1695/rs4891 polymorphisms included only one heterozygous type and one homozygous type. The allele frequencies of the three SNPs were 21.6%, 2.9%, and 21.6%. The AG+GG/TC+CC genotype of GSTP1 rs1695/rs4891 was associated with decrease in the odds of peripheral hemoglobin (OR=0.25, 95%CI=0.06-1.00, P=0.049). The AG+GG/TC+CC genotype of GSTP1 rs1695/rs4891 in standard and intermediate-risk ALL children was significantly correlated with higher odds of gastrointesti-nal toxicity (OR=0.125, 95%CI=0.02-0.78, P=0.026). Conclusion:GSTP1 rs1695 (A313G)/rs4891 (T555C) gene polymorphism is as-sociated with the reduction of peripheral hemoglobin in ALL children and with the odds of gastrointestinal toxicity in standard and inter-mediate-risk ALL children who receive high-dose methotrexate.